Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:atccode |
B01 AC24
|
| gptkbp:brand |
gptkb:Brilinta
|
| gptkbp:chemical_formula |
C23 H28 F2 N6 O4 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
stenting procedures
secondary prevention |
| gptkbp:contraindication |
active bleeding
severe renal impairment severe liver impairment hypersensitivity to ticagrelor |
| gptkbp:developed_by |
gptkb:Astra_Zeneca
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
as prescribed by a physician
|
| gptkbp:effective_date |
gptkb:2011
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
ticagrelor
|
| gptkbp:indication |
gptkb:Cardiology
acute coronary syndrome |
| gptkbp:ingredients |
gptkb:ticagrelor
|
| gptkbp:interacts_with |
aspirin
CYP3 A4 inducers CYP3 A4 inhibitors |
| gptkbp:is_monitored_by |
liver function tests
hemoglobin levels platelet function kidney function tests |
| gptkbp:lifespan |
7 hours
|
| gptkbp:mechanism_of_action |
P2 Y12 receptor antagonist
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:name |
essential medicines
|
| gptkbp:patient_education |
take with or without food
report unusual bleeding do not stop taking without consulting a doctor avoid NSAIDs |
| gptkbp:patient_population |
adults
|
| gptkbp:pharmacokinetics |
rapid absorption
inhibits platelet aggregation |
| gptkbp:research_focus |
patient adherence
drug interactions long-term safety dosing strategies cardiovascular outcomes |
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_measures |
regular blood tests
|
| gptkbp:side_effect |
dizziness
headache nausea bruising gastrointestinal bleeding bleeding dyspnea |
| gptkbp:trade |
Brilique
|
| gptkbp:used_for |
preventing blood clots
|
| gptkbp:bfsParent |
gptkb:Brilinta
|
| gptkbp:bfsLayer |
5
|